Home › Liposarcoma
Liposarcoma clinical trials recruiting in the U.S.
17 studies for Liposarcoma are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX10 studies
- Boston, MA7 studies
- Chicago, IL5 studies
- New York City, NY5 studies
- Queens, NY5 studies
- St. Louis, MO5 studies
- Edison, NJ4 studies
- Atlanta, GA4 studies
- Seattle, WA3 studies
- Rochester, MN3 studies
- New Rochelle, NY3 studies
- Greenburgh, NY3 studies
- Columbus, OH3 studies
- San Diego, CA3 studies
- Gainesville, FL3 studies
- Phoenix, AZ3 studies
- Tampa, FL3 studies
- Nashville, TN3 studies
- Louisville, KY3 studies
- Richmond, VA3 studies
- Miami, FL3 studies
- Pittsburgh, PA3 studies
- Aurora, CO3 studies
By state
- Arizona3 studies
- California6 studies
- Colorado3 studies
- Connecticut3 studies
- Florida4 studies
- Georgia4 studies
- Illinois5 studies
- Kentucky3 studies
- Massachusetts7 studies
- Michigan4 studies
- Minnesota3 studies
- Missouri5 studies
- New Jersey5 studies
- New York6 studies
- Ohio6 studies
- Pennsylvania4 studies
- Tennessee4 studies
- Texas11 studies
- Virginia5 studies
- Washington3 studies
Recently updated studies
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06881992Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06422806A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for Liposarcomas
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT06025747A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06843967Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT04031677Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06578624Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT05711615Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RecruitingPhase 1/2
Up to age 30 · All sexes · Updated Sep 3, 2026 · NCT06541262STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT06975293Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
RecruitingPhase 1
Ages 1 to 21 · All sexes · Updated Aug 6, 2026 · NCT04715191NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
RecruitingPhase 1/2
Up to age 30 · All sexes · Updated Aug 3, 2026 · NCT06239272A Study of Pembrolizumab in People With Ultra-Rare Sarcomas
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 28, 2026 · NCT07089992Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT07377747Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 17, 2026 · NCT06498648A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 11, 2026 · NCT06789172Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
RecruitingPhase 1
Ages 1 to 26 · All sexes · Updated Feb 17, 2026 · NCT07148050Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RecruitingPhase 1
Up to age 21 · All sexes · Updated Nov 3, 2025 · NCT06198296From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.